Takeda Pharmaceutical Ltd ADR (TAK) Stock Price, Quote & News

Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate,...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 81 3 3278-2111

Fax: 81 3 3278-2000

Website: www.takeda.com

Address:

1-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo, Japan

jozef56 Jul. 15 at 1:57 PM

$ALKS $BIIB $TAK $AXSM $CNTA also golman sacks has his own agenda ...never trust analysts

0 · Reply

Quantumup Jul. 15 at 1:18 PM

Goldman Sachs🏁 $ALKS But/$43. $BIIB $TAK $AXSM JAZZ $CNTA Goldman Sachs said in its initiation report:

0 · Reply

Posporino Jul. 14 at 6:44 PM

$TAK When is it paying dividend?

0 · Reply

Thestocktraderhubzee Jul. 14 at 9:58 AM

WATCHLIST JUL 14 2025 $UVV Universal Announces Retirement Of Johan Kroner As SVP And CFO; Company Initiates Search For Successor $CLBR Colombier II Reveals Minimal Redemptions In Connection With Business Combination With GrabAGun; Expects To Deliver Over $179.1M Of Gross Proceeds To GrabAGun Digital; Business Combination Expected To Close On July 15, 2025 $TDS United States Cellular Corporation And Telephone and Data Systems Receive FCC Approval Regarding Sale Of Wireless Operations And Select Spectrum Assets $TAK Takeda's Oveporexton Demonstrates Safety and Efficacy in Global Phase 3 Studies, Paving Way For New Narcolepsy Treatment $HIMX Himax and Rabboni Launch World's First AI Sensing System for Wearables, Promising Smarter, Longer-Lasting Devices

0 · Reply

BigSqueezeComing Jul. 14 at 9:16 AM

$TAK https://www.businesswire.com/news/home/20250714054710/en/Takeda-Announces-Positive-Results-from-Two-Pivotal-Phase-3-Studies-of-Oveporexton-TAK-861-in-Narcolepsy-Type-1 pt $20+

0 · Reply

Quantumup Jul. 11 at 3:03 PM

Goldman Sachs, on 7/10,🏁 $NBIX Buy-$182. $CRNX $TAK $BMY Goldman Sachs said in its initiation report:

0 · Reply

Quantumup Jul. 9 at 10:24 AM

UBS⬆️ $NBIX PT to $174 from $152, reiterated Buy and said, "Lot less polarized vs 4Q24 and 1Q25 set-up: we expect outperformance at 2Q" $CRNX $TAK UBS added, "We continue to see steady upside on the stock for remainder of 2025. For the stock to break from the recent range-bound action, we believe consistently strong uptake on Crenessity is key. Based on our incomings, we believe the stock is lot less polarized heading into the 2Q25 print, as opposed to 4Q24 (Crenessity elevated expectations) and 1Q25 (Ingrezza bear case). We are raising our PT to $174 (from $152) based on 5.25x EV/'30E sales (prior 4.5x), supported by a DCF; we increase our multiple to reflect an increasing growth narrative with early bullish indicators for Crenessity launch. Crenessity physician checks indicate 400+ new patient starts realistic in 2Q" UBS went on to say:

0 · Reply

Quantumup Jul. 2 at 4:04 PM

Benchmark: July 1st: $UNCY: Note Regarding CRL Issue: Unicycive ( $UNCY ) Will Seek Type A Meeting to Resolve CRL Issues $TAK $ARDX $SNY $AKBA FMS Benchmark said in its note:

2 · Reply

SparkyReturns Jun. 25 at 7:52 PM

$BMY Umm, Remember the tip I gave yesterday about ICU? Yeah.... UP 16%. Just getting started. $GSK $REGN $TAK

0 · Reply

ZacksResearch Jun. 25 at 1:26 PM

$ADMA or $TAK: Which stock is your better bet? 🤔 ADMA’s Asceniv is seeing record demand with plans to file for a label expansion in mid-2025, while TAK’s diverse portfolio and R&D efforts drive its plasma-derived therapies. Yet, ADMA’s growth prospects shine brighter despite its higher valuation. Discover why ADMA might be your top choice now 👉 https://www.zacks.com/commentary/2553269/adma-vs-takeda-which-plasma-therapy-stock-is-the-better-buy-today?cid=sm-stocktwits-2-2553269-body-58&ADID=SYND_STOCKTWITS_TWEET_2_2553269_BODY_58

0 · Reply

Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1

Jun 30, 2025, 8:00 AM EDT - 15 days ago

Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1

Jun 25, 2025, 3:07 AM EDT - 20 days ago

Takeda Announces New Assignments of Directors

Jun 3, 2025, 10:12 AM EDT - 6 weeks ago

European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD

Jun 1, 2025, 8:00 AM EDT - 6 weeks ago

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

PTGX

May 27, 2025, 7:30 AM EDT - 7 weeks ago

Takeda and Nature Announce Call for Applications Now Open for 2026 Innovators in Science Award

May 14, 2025, 5:03 PM EDT - 2 months ago

The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1

May 11, 2025, 8:30 AM EDT - 2 months ago

Takeda Pharmaceuticals Caps A Strong Year, Guidance Suggests Dividend Is On The Rise

May 9, 2025, 9:26 AM EDT - 2 months ago

Takeda Pharmaceutical Company Limited (TAK) Q4 2024 Earnings Call Transcript

May 8, 2025, 11:54 PM EDT - 2 months ago

Takeda Pharma less impacted by tariff, yen headwinds than other Japanese drugmakers: CEO

May 8, 2025, 10:32 AM EDT - 2 months ago

Japanese Pharma Company Takeda Expects Limited Exposure To US-China Tariffs

May 8, 2025, 2:36 AM EDT - 2 months ago

Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress

May 5, 2025, 8:00 AM EDT - 2 months ago

BioLife Plasma Services Introduces the New Fresenius Kabi Adaptive Nomogram Across its U.S. Network of Plasma Donation Centers

Apr 30, 2025, 8:05 AM EDT - 2 months ago

Takeda Awards $13.8 Million to U.S. Nonprofit Partners to Promote Healthy Eating and Expand STEM Education

Apr 8, 2025, 7:15 AM EDT - 3 months ago

BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3

XOMA

Apr 1, 2025, 2:27 PM EDT - 3 months ago

Takeda & Protagonist: Rusfertide Clinical Success Bolsters Investment Returns

Mar 13, 2025, 3:45 AM EDT - 4 months ago

Takeda: Buy Into Future Drug Pipeline Potential, Despite Recent Profit Headwinds

Mar 3, 2025, 6:45 AM EST - 4 months ago

Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

PTGX

Feb 24, 2025, 3:01 AM EST - 5 months ago

The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)

Jan 31, 2025, 8:30 AM EST - 5 months ago

Strong Q3, Improved Guidance Are Signs Takeda Pharmaceutical May Be Undervalued

Jan 30, 2025, 4:45 PM EST - 5 months ago

Takeda Pharmaceutical Company Limited (TAK) Q3 2025 Earnings Call Transcript

Jan 30, 2025, 9:00 AM EST - 5 months ago

Suffolk Celebrates Topping off for a Game-Changing New Takeda Facility in Kendall Square Where Science, Art and Community Will Converge

Jan 30, 2025, 2:04 AM EST - 5 months ago

Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026

Jan 30, 2025, 1:43 AM EST - 5 months ago

Japan's Takeda says Q3 profit slid 38%, trailing analyst estimates

Jan 30, 2025, 1:35 AM EST - 5 months ago

Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin Growth

Jan 23, 2025, 7:14 PM EST - 6 months ago

Takeda-backed Ascentage Pharma aims to raise $126 mln in US IPO

Jan 21, 2025, 6:24 AM EST - 6 months ago

Takeda-backed Ascentage Pharma targets $1.75 billion valuation in US IPO

Dec 27, 2024, 1:00 AM EST - 7 months ago

Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

Dec 12, 2024, 5:30 PM EST - 7 months ago

Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas

Dec 7, 2024, 8:00 AM EST - 7 months ago

Takeda Pharmaceutical: Dividend Yield Is High But Hides Pitfalls Especially For US Investors

Dec 3, 2024, 12:37 PM EST - 8 months ago

Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst

KROS

Dec 3, 2024, 7:00 AM EST - 8 months ago

Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics

KROS

Nov 20, 2024, 11:30 AM EST - 8 months ago

Alloy Therapeutics Signs Collaboration and License Agreement with Takeda to Develop Cell Therapy Platform

Nov 15, 2024, 3:33 PM EST - 8 months ago

Hennessy Japan Fund's Masa Takeda on the top Japanese stocks investors should watch

Oct 31, 2024, 11:02 PM EDT - 9 months ago

Takeda Pharmaceutical Company Limited (TAK) Q2 2025 Earnings Call Transcript

Oct 31, 2024, 2:15 AM EDT - 9 months ago

Japan's Takeda returns to Q2 profit as drugmaker recovers from impairments

Oct 31, 2024, 2:05 AM EDT - 9 months ago

Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook

Oct 24, 2024, 8:00 AM EDT - 9 months ago

Takeda and Boston Medical Center Announce Innovative Collaboration to Help Tackle Decarbonization Across Health Care Ecosystem

Oct 7, 2024, 9:36 AM EDT - 10 months ago

Takeda Pharmaceuticals: An Interesting Option For Income Investors

Sep 26, 2024, 8:30 AM EDT - 10 months ago

Tempus Announces Expansion of Collaboration with Takeda to Leverage Multimodal Real-World Datasets and Biological Model Systems in Oncology Research and Development

TEM

Sep 24, 2024, 3:00 AM EDT - 10 months ago

Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer

Sep 19, 2024, 8:00 AM EDT - 10 months ago

Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK-861 on the Burden of Narcolepsy at Sleep Europe 2024

Sep 18, 2024, 10:00 AM EDT - 10 months ago

Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries

Sep 4, 2024, 7:00 AM EDT - 11 months ago

US allows increased production of Takeda's ADHD drug to address shortage

Aug 12, 2024, 10:42 AM EDT - 1 year ago

Ascendis' Hypoparathyroidism Drug Scores FDA Approval As First and Only Treatment, Replacing Takeda's Drug Discontinued Due To Supply Issues

Aug 7, 2024, 2:29 PM EDT - 1 year ago

Why Is Japanese Drugmaker Takeda Pharmaceutical Stock Trading Higher On Wednesday?

Aug 7, 2024, 6:45 AM EDT - 1 year ago

Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Aug 2, 2024, 3:21 PM EDT - 1 year ago

Takeda Pharmaceutical Company Limited (TAK) Q1 2025 Earnings Call Transcript

Aug 1, 2024, 8:00 AM EDT - 1 year ago

BostonGene Announces Partnership with Takeda to Evaluate Immunotherapies Using AI-Powered Molecular Profiling

Jul 31, 2024, 2:06 AM EDT - 1 year ago

Takeda Announces First Quarter FY2024 Results - Strong Performance by Growth & Launch Products; Advancements in Promising Late-Stage Pipeline

jozef56 Jul. 15 at 1:57 PM

$ALKS $BIIB $TAK $AXSM $CNTA also golman sacks has his own agenda ...never trust analysts

0 · Reply

Quantumup Jul. 15 at 1:18 PM

Goldman Sachs🏁 $ALKS But/$43. $BIIB $TAK $AXSM JAZZ $CNTA Goldman Sachs said in its initiation report:

0 · Reply

Posporino Jul. 14 at 6:44 PM

$TAK When is it paying dividend?

0 · Reply

Thestocktraderhubzee Jul. 14 at 9:58 AM

0 · Reply

BigSqueezeComing Jul. 14 at 9:16 AM

$TAK https://www.businesswire.com/news/home/20250714054710/en/Takeda-Announces-Positive-Results-from-Two-Pivotal-Phase-3-Studies-of-Oveporexton-TAK-861-in-Narcolepsy-Type-1 pt $20+

0 · Reply

Quantumup Jul. 11 at 3:03 PM

Goldman Sachs, on 7/10,🏁 $NBIX Buy-$182. $CRNX $TAK $BMY Goldman Sachs said in its initiation report:

0 · Reply

Quantumup Jul. 9 at 10:24 AM

0 · Reply

Quantumup Jul. 2 at 4:04 PM

Benchmark: July 1st: $UNCY: Note Regarding CRL Issue: Unicycive ( $UNCY ) Will Seek Type A Meeting to Resolve CRL Issues $TAK $ARDX $SNY $AKBA FMS Benchmark said in its note:

2 · Reply

SparkyReturns Jun. 25 at 7:52 PM

$BMY Umm, Remember the tip I gave yesterday about ICU? Yeah.... UP 16%. Just getting started. $GSK $REGN $TAK

0 · Reply

ZacksResearch Jun. 25 at 1:26 PM

0 · Reply

ZacksResearch Jun. 25 at 11:57 AM

$ADMA vs. $TAK — which plasma play wins in 2025? Asceniv demand is ramping hard, and ADMA’s revenue outlook is getting bolder — this isn’t your typical underdog story. Full breakdown of the bullish setup here 👉 https://www.zacks.com/stock/news/2553269/adma-vs-takeda-which-plasma-therapy-stock-is-the-better-buy-today?cid=sm-stocktwits-2-2553269-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2553269_TEASER

0 · Reply

biotech Jun. 25 at 11:12 AM

$SGMO So Sangamo CEO worked at $TAK and $GSK Sangamo hiring for London Prion done in UK mentioning Fabry , Sickle Cell and Tregs in #London hire not mentioning Hemophilia so a fabry partner could sit in Europe (UK) and getting T-regs (trial done in Europe too) sickle cell on top?

1 · Reply

SparkyReturns Jun. 24 at 3:33 PM

$TAK Something to look at. Small cap investing idea: ICU recently beat down from a capital raise a few days ago, which was just reported will make them Nasdaq compliant. Waiting on confirmation. ICU has a unique SCD device which treats Acute Kidney Infection and has also been approved for compassionate and emergency use for Sepsis. FDA loves it so much has granted multiple breakthrough device designations, and has even awarded grants. Also Dept of Defense money to study use in burn or trauma cases. The device can calm the cytokine storm which can happen in a variety of conditions from AKI to sepsis to heart attacks to burn cases, Covid, etc. TAM in the tens of Billions. Current market cap approx. 8M. Read that again. Let that sink in. Reversal incoming. Cheers! $SYK $DVA $FMS

0 · Reply

biotech Jun. 24 at 12:34 PM

$SGMO +1.74 mL #gain of kidney function ... VS #losing kidney funktion with $TAK Replagal (agalsidase alfa), $SNY Fabrazyme (agalsidase beta) and $FOLD Galafold (migalastat) marketed treatment options range from -2.2 to -0.4 mL/min/1.73m2/year

0 · Reply

Quantumup Jun. 20 at 7:40 PM

Goldman Sachs, on 6/16,🏁 $ELVN Buy-$37. $TERN $AAPG $TAK INCY $NVS PFE BMY AZN #EHA2025 Goldman Sachs said in its initiation report: "Given continued positive Ph1 data and the announcement of a planned Ph3 initiation in 2026 for tyrosine kinase inhibitor (TKI) ELVN-001 in chronic myeloid leukemia (CML), we assign a Buy rating to $ELVN with a $37, 12-month price target, from the previous Early-Stage Biotech designation." Goldman Sachs went on to say:

1 · Reply

Quantumup Jun. 20 at 5:50 PM

TD Cowen Named Buy Rated $ELVN as a Best Smidcap Idea and said "Strong Data Position '001 To Advance Care In $B+ CML Market" $TERN $AAPG $TAK $NVS PFE AZN BMY #EHA2025 TD Cowen additionally said, "ELVN-001 is designed to improve upon prior TKIs for CML. At EHA ELVN-001 produced strong proof-of-concept data with a high MMR rate and benign safety profile, positioning it to become a standard therapy in this multi-$B market. ELVN-001 will enter pivotal development in 2026 and we project peak sales of $3B. We think $ELVN is undervalued for '001's potential. It is a top smidcap biotech pick."

0 · Reply

Quantumup Jun. 17 at 7:52 PM

Stifel reitd $ALKS Buy-$42~"We remain Buy on $ALKS into the upcoming NT1 readout for ALKS2680, coming early-3Q. [ $TAK] Bottom line: the risk/reward on this specific catalyst isn't great, simply because investors mostly expect NT1 to be positive. However, our thesis here continues to center around a view that: (1) ALKS2680 is likely to succeed in NT1 and beyond--including in "normal" orexin populations like NT2/IH and (2) the Street's safety concerns with '2680--visual disturbances, etc.--are probably overdone. To this point, assuming the NT1 trial succeeds, safety/tolerability, and nuances around the ALKS2680 dose response, may end up being the most important points with implied readthrough onto prospects in NT2 (data this fall). The other question for NT1 is whether Takeda--with TAK-861--leaves any room for clinical differentiation. Admittedly while we think '2680 is a more potent drug with superior (QD) dosing, the bar is high; there is some, but not much, room on MWT, cataplexy and CGI-I."

0 · Reply

Quantumup Jun. 17 at 1:43 PM

Citi🏁 $PTGX Buy-$72. $TAK $JNJ Citi said in its note, "We are initiating coverage on Protagonist with a Buy/HR rating and a $72 target price, driven primarily by the potential of rusfertide (partnered with Takeda) in polycythemia Vera (PV) and oral IL-23 (icotrokinra - partnered with JNJ) in multiB$ inflammation indications. While we acknowledge share outperformance over 3 months (+40% vs +2% SPY), we believe rusfertide's impressive efficacy as demonstrated in phase 3 including improvement in QOL scores suggests the drug has strong potential in PV patients as despite therapeutic advancement there still remains unmet need. Rusfertide also has the potential to be added to therapies which could expand its use. However, we believe despite excellent efficacy and safety profile, cost-effectiveness still remains a concern, resulting in our in-line sales estimates (2032 combined WW revenues of $700M vs $680M VA cons)."

0 · Reply

Night_Owl_Biotech Jun. 16 at 2:29 PM

The attachment compares $ARDX & $PHAT valuations (market cap & EV) versus cumulative projected revenues per analysts & estimated gross margins using FY24 actuals through patent expiration. ARDX's Tenapanor has 2 brands, one of which is patented thru FY33 & the other thru FY34. PHAT's Voquezna is patented thru 5/2/32. Both appear to trade at roughly the same multiple of cumulative projected revenues thru FY34. ARDX trades at a slightly lower multiple of estimated gross margins (using actual FY24 as an estimate). PHAT pays $TAK a royalty which is the primary reason for the variance. PHAT's debt is a royalty obligation (that may dramatically skew comparisons). It's been our unqualified opinion ARDX offers a better risk v. reward profile after PHAT's recent run (but of course we could be wrong). We're curious to learn perspectives from PHAT investors. This is not investment advice. $XBI $NBI

1 · Reply

Love_To_Learn Jun. 13 at 10:28 AM

$TAK will need u for something important actually

0 · Reply

Quantumup Jun. 11 at 12:48 PM

H.C. Wainwright reiterated $UNCY Buy-$9 $TAK $SNY $ARDX $AKBA FMS H.C. Wainwright said in its note: "On June 10, Unicycive management announced that the FDA has identified a cGMP compliance-related deficiency with the company's third-party manufacturing vendor. The vendor in question is a subcontractor to Unicycives contract manufacturer (CDMO) and provides mostly fill/finish services for manufacturing OLC. Management reported that other than this issue, the FDA has not identified any other safety, efficacy, or manufacturing issues with the NDA submission. H.C. Wainwright went on to say:

1 · Reply

Market Cap	46.71B
Revenue (ttm)	30.24B
Net Income (ttm)	712.32M
EPS (ttm)	N/A
PE Ratio	9.39
Forward PE	8.68
Profit Margin	2.36%
Debt to Equity Ratio	0.65

Volume	3,701,000
Avg Vol	2,209,356
Day's Range	N/A - N/A
Shares Out	3.18B
Stochastic %K	46%
Beta	0.23
Analysts	Strong Sell
Price Target	$16.67